A section 1 trial has initiated and is investigating remedy with ziftomenib plus Gleevec in superior GIST: © inventory.adobe.com.
The primary affected person has been dosed in a section 1 trial investigating ziftomenib plus Gleevec (imatinib) in superior gastrointestinal stromal tumors (GIST) following development with Gleevec, in line with a information launch from Kura Oncology.
As well as, the corporate introduced that the mix has proven strong and sturdy antitumor exercise in Gleevec-sensitive and Gleevec-resistant GIST in preclinical fashions.
“Constructing on compelling scientific exercise of ziftomenib in sufferers with NPM1-mutant and KMT2A-rearranged [acute myeloid leukemia], we’re dedicated to evaluating the total therapeutic potential of menin inhibitors for the remedy of most cancers,” Dr. Mollie Leoni, chief medical officer of Kura Oncology, stated within the information launch.
Glossary:
Total response price (ORR): share of sufferers whose most cancers shrinks or disappears after remedy.
Development-free survival (PFS): time throughout and after remedy {that a} affected person lives with out most cancers rising or spreading.
Period of response (DOR): size of time a remedy retains most cancers underneath management after it first responds.
Total survival (OS): time from remedy begin or prognosis till loss of life from any trigger.
She continued, “Roughly 4,000 to six,000 new instances of GIST are recognized annually within the U.S., and superior GIST sufferers have restricted remedy choices. Our preclinical information show the mix of ziftomenib and [Gleevec] supplies strong and sturdy antitumor exercise in each Gleevec-sensitive (1L) and [Gleevec]-resistant (2L/3L) GIST patient-derived xenograft fashions, and we look ahead to seeing whether or not the mix gives potential to remodel the remedy paradigm.”
In preclinical research, information present the mix has antitumor exercise by way of an artificial deadly mechanism, as ziftomenib epigenetically targets a GIST tumor weak point attributable to ineffective tyrosine kinase inhibitors. Sixty p.c of sufferers develop resistance to Gleevec, the frontline normal of look after GIST, inside two years, and ziftomenib might assist delay or overcome that resistance.
The section 1a/1b, open-label, dose-escalation KOMET-015 trial is evaluating the security, tolerability and early antitumor exercise of ziftomenib plus Gleevec in adults with GIST whose illness progressed throughout or after Gleevec remedy. After the dose-escalation portion, enlargement cohorts will assess security, tolerability and scientific exercise. Main aims embody evaluating security and tolerability and figuring out the really helpful section 2 dose. Secondary finish factors embody scientific profit, total response price, progression-free survival, length of response and total survival.
“This examine is a vital step in creating new mixture remedies to doubtlessly enhance outcomes for sufferers with superior GIST, a illness indication for which new therapeutic choices are wanted,” Dr. Mrinal Gounder, sarcoma oncologist & early section drug growth specialist at Memorial Sloan Kettering Most cancers Middle, stated within the information launch. “KOMET-015 builds upon the promising preclinical information noticed with ziftomenib together with Gleevec in GIST fashions and we look ahead to evaluating the investigational drug candidate and its potential to remodel the remedy panorama.”
At present, no different scientific trials are finding out a menin inhibitor mixed with normal remedies for GIST.
Ziftomenib, an investigational oral menin inhibitor taken as soon as each day, is in growth for genetically outlined acute myeloid leukemia and gastrointestinal stromal tumor. In April 2024, the Meals and Drug Administration granted breakthrough remedy designation to ziftomenib for the remedy of relapsed or refractory NPM1-mutant acute myeloid leukemia, primarily based on findings from Kura Oncology’s KOMET-001 trial.
“Till now, most approaches to treating GIST depend on focused KIT inhibition by way of tyrosine kinase inhibitors equivalent to Gleevec, nevertheless most sufferers finally progress because of acquired secondary KIT mutations highlighting the necessity for brand spanking new remedy choices,” Dr. Shreyaskumar Patel, heart medical director, Sarcoma Middle, at The College of Texas MD Anderson Most cancers Middle, stated within the information launch. “We’re extremely inspired by the substantial preclinical information generated to this point supporting the mix for ziftomenib together with KIT inhibitors in superior GIST, and the dosing of the primary sufferers marks an vital milestone to deal with the significant unmet want for these sufferers.”
For extra info concerning the KOMET-015 trial, please go to www.clinicaltrials.gov utilizing the identifier: NCT06655246.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
